Table 1.

EGFR ECD mutations identified in patients with colorectal cancer and response to anti-EGFR drugs cetuximab (CTX), panitumumab (PNM), and Sym004, including summary of the functional, cell viability, biochemical studies, and clinical results

Drug–receptor bindingInhibition of EGFR phosphorylationDrug sensitivityEGFR downstream signaling inhibitionPatient's response
EGFR mutationCTXPNMSym004CTXPNMSym004CTXPNMSym004CTXPNMSym004PNMSym004
S492RNoYesYesNoYesYesRSSNoYesYesYesYes
R451CModerateModerateModerateYesYesYesaa
K467TNoYesYesNoYesYesaa
G465RNoNoYesNoNoYesRRSNoNoYesNoYes
  • Abbreviations: R, resistant; S, sensitive.

  • *No existing preclinical model.

  • aNonevaluated in patients.